Tony Jiang

Q: What is Tony Jiang email address?

Email Tony Jiang at tjiang@amgen.com. This email is the most updated Tony Jiang email found in 2026.

Q: How to contact Tony Jiang?

To contact Tony Jiang send an email to tjiang@amgen.com. (updated on October 29, 2024)

Senior Director Biostatistics - Oncology Global Development at Amgen | Los Angeles Metropolitan Area

About Tony Jiang

Tony Jiang is an accomplished biostatistician currently serving as the Director of Biostatistics in Oncology Global Development at Amgen. With a robust background in Oncology, Inflammation, and Cardiovascular disease, Tony brings a wealth of expertise in clinical program design strategy and innovative statistical analyses. His current focus is on leading the global statistical strategy for Tarlatamab, a DLL3-targeted bispecific antibody designed to combat small cell lung cancer. This pivotal role not only underscores his proficiency in biostatistics but also highlights his commitment to advancing cancer treatment through rigorous statistical methodologies.

In addition to his work on Tarlatamab, Tony spearheads a centralized R analytic team dedicated to enhancing data visualization and statistical modeling. His expertise in R, Bayesian statistics, and survival analysis enables him to implement cutting-edge analytical techniques that drive insights and inform decision-making processes in clinical trials. By leveraging tools such as SAS and WinBUGS, he ensures that the statistical frameworks employed are both robust and adaptable to the evolving landscape of oncology research.

Tony's leadership in these key projects exemplifies his ability to integrate complex statistical concepts with practical applications in drug development. His contributions not only facilitate the successful progression of clinical trials but also enhance the overall understanding of treatment efficacy and safety in oncology. As a thought leader in biostatistics, Tony Jiang continues to shape the future of cancer therapeutics, making significant strides toward improving patient outcomes in small cell lung cancer and beyond.

Tony Jiang Work